These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30993607)

  • 1. The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy.
    Oh SJ; Fan X
    CNS Drugs; 2019 Jun; 33(6):539-547. PubMed ID: 30993607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan, its potential therapeutic implications in cardiometabolic disorders.
    Yamagishi S; Nakamura K
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):79-83. PubMed ID: 18221077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
    Yamagishi S; Takenaka K; Inoue H
    Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV protease inhibitors activate the adipocyte renin angiotensin system.
    Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
    Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
    Yamagishi S; Nakamura K; Matsui T
    Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.
    Borém LMA; Neto JFR; Brandi IV; Lelis DF; Santos SHS
    Hypertens Res; 2018 Jun; 41(6):394-405. PubMed ID: 29636553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the renin-angiotensin system in migraine.
    Tronvik E; Stovner LJ; Schrader H; Bovim G
    J Hypertens Suppl; 2006 Mar; 24(1):S139-43. PubMed ID: 16601567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
    Kurtz TW; Pravenec M
    J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review.
    Almeida-Santos AF; Kangussu LM; Campagnole-Santos MJ
    Protein Pept Lett; 2017 Nov; 24(9):841-853. PubMed ID: 28828974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system blocking drugs.
    Robles NR; Cerezo I; Hernandez-Gallego R
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats.
    Awwad ZM; El-Ganainy SO; ElMallah AI; Khattab MM; El-Khatib AS
    Toxicology; 2019 Dec; 428():152310. PubMed ID: 31629013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
    Georgescu EF
    Adv Ther; 2008 Nov; 25(11):1141-74. PubMed ID: 18972077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan: just an antihypertensive agent? A literature review.
    Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
    Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
    Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
    Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence.
    Fouda AY; Artham S; El-Remessy AB; Fagan SC
    Clin Sci (Lond); 2016 Feb; 130(4):221-38. PubMed ID: 26769658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.